CBD Epilepsy Trial Liver-Enzyme Events Often Involved Concomitant Valproate
Liver-enzyme events during CBD epilepsy trials often occurred in patients also taking valproate. That pattern makes the full medication regimen important, but it does not isolate which drug caused an individual event or establish safety without valproate.
The finding came from treated epilepsy populations
An original reanalysis of four randomized trials examined highly purified oral CBD in Lennox–Gastaut and Dravet syndromes. CBD or placebo was added to existing antiseizure regimens for fourteen weeks. Patients commonly received multiple concomitant medicines.
The safety analysis distinguished laboratory reports of increased aspartate aminotransferase (AST) and alanine aminotransferase (ALT) from other adverse events. These are blood-based clinical laboratory endpoints; they are not urine cannabinoid-screen results or measurements of THC impairment.
Valproate was frequent among enzyme-event cases
The report’s narrative states that most CBD-treated Lennox–Gastaut patients with increased AST or ALT were taking valproate. It reports concomitant valproate in all Dravet CBD recipients with those respective enzyme-event reports. Clobazam was also common, but the authors emphasized the greater involvement of valproate in this pattern.
Those are descriptions among event cases. They should not be misread as the percentage of all valproate recipients who developed an elevation. That risk calculation requires the appropriate exposed denominator, a consistent event definition and a suitable comparison group.
Co-treatment was not randomized
Patients were randomized to CBD or placebo, not to valproate use. Disease severity, previous treatment choices and other drugs could differ between regimens. The analysis did not fully account for the influence of all concomitant medicines, and medication doses could change after adverse effects.
An enzyme elevation also does not, by itself, define clinical hepatitis, explain every liver injury or establish a universal dosing rule. The paper’s subgroup observations support reviewing treatment chronology, baseline tests, subsequent laboratory trends and the complete regimen.
These safety findings and the report’s seizure-efficacy analyses use existing trial data. They should not be counted as independent new patient cohorts. They also do not transfer directly to every retail CBD product, dose or healthy consumer.
Related: why CBD interaction review includes active metabolites and the full regimen.
Primary research
Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials. DOI: 10.1111/ane.13351.
